《大行》中銀國際降布魯可(00325.HK)目標價至132.7元 續予「買入」評級
中銀國際發表研究報告指,布魯可(00325.HK)上半年收入按年增長28%,惟經調整淨利潤僅升10%,遜市場較高的預期。由於公司延遲發布產品,拖累期內收入,加上公司的提前支出,或會影響其短期盈利能力。然而,隨著公司準備推出更多產品,預計下半年的收入按年增長增長將加快至70至80%。
該行認為,布魯可需要時間來證明其穩定交付盈利的能力,但預計其強大的IP組合將使其在國內和海外市場具備高度競爭力,維持「買入」評級,目標價由174.1元下調至132.7元,而其2025至27財年盈測則分別降24%、20%及17%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.